• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pembrolizumab Monotherapy for Early-Stage Triple-Negative Breast Cancer in a Patient With Lynch Syndrome.

作者信息

Gowda Sonia, Song Fei, Young Shannon, Simshauser Erika, Aleali Seyedeh, Elkon Jacob, Garber Judy E, Schlam Ilana

机构信息

Division of Hematology and Oncology, Tufts Medical Center, Boston, MA.

Department of Radiology, Tufts Medical Center, Boston, MA.

出版信息

JCO Precis Oncol. 2025 Apr;9:e2400646. doi: 10.1200/PO-24-00646. Epub 2025 Apr 28.

DOI:10.1200/PO-24-00646
PMID:40294353
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12052070/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a3b/12052070/a1c013fa99a2/po-9-e2400646-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a3b/12052070/22ccd0c485d8/po-9-e2400646-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a3b/12052070/a1c013fa99a2/po-9-e2400646-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a3b/12052070/22ccd0c485d8/po-9-e2400646-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a3b/12052070/a1c013fa99a2/po-9-e2400646-g002.jpg

相似文献

1
Pembrolizumab Monotherapy for Early-Stage Triple-Negative Breast Cancer in a Patient With Lynch Syndrome.帕博利珠单抗单药治疗林奇综合征患者的早期三阴性乳腺癌
JCO Precis Oncol. 2025 Apr;9:e2400646. doi: 10.1200/PO-24-00646. Epub 2025 Apr 28.
2
A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.患者存在 MSH6 胚系突变致林奇综合征，使用派姆单抗治疗后获得持久缓解：一例子宫浆液性癌病例报告
Oncologist. 2021 Oct;26(10):811-817. doi: 10.1002/onco.13832. Epub 2021 Jun 14.
3
The cost-effectiveness of treatment for high-risk, early-stage, triple-negative breast cancer in Egypt: an analysis of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab.埃及高危早期三阴性乳腺癌治疗的成本效益：新辅助派姆单抗联合化疗后序贯辅助单药派姆单抗的分析
J Med Econ. 2025 Dec;28(1):105-113. doi: 10.1080/13696998.2024.2441073. Epub 2025 Jan 3.
4
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.帕博利珠单抗联合化疗对比安慰剂联合化疗用于治疗既往未经治疗的局部晚期不可切除或转移性三阴性乳腺癌（KEYNOTE-355）：一项随机、安慰剂对照、双盲、III 期临床研究。
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.
5
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer.TROPION-Breast04：一项关于新辅助达妥昔单抗（Dato-DXd）联合度伐利尤单抗治疗，随后辅助使用度伐利尤单抗与初治早期三阴性或激素受体低表达/人表皮生长因子受体2阴性乳腺癌患者的标准治疗方案对比的随机III期研究。
Ther Adv Med Oncol. 2025 Feb 5;17:17588359251316176. doi: 10.1177/17588359251316176. eCollection 2025.
6
Pembrolizumab for Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌。
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.
7
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.帕博利珠单抗对比研究者选择化疗用于转移性三阴性乳腺癌（KEYNOTE-119）：一项随机、开放标签、III 期临床试验。
Lancet Oncol. 2021 Apr;22(4):499-511. doi: 10.1016/S1470-2045(20)30754-3. Epub 2021 Mar 4.
8
OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer.OptimICE-RD：Sacituzumab govitecan+pembrolizumab 对比 pembrolizumab（±卡培他滨）用于治疗残留三阴性乳腺癌。
Future Oncol. 2024;20(31):2343-2355. doi: 10.1080/14796694.2024.2357534. Epub 2024 Jun 26.
9
Efficacy and safety of pembrolizumab based therapies in triple-negative breast cancer: A systematic review of clinical trials.帕博利珠单抗为基础的治疗方案在三阴性乳腺癌中的疗效和安全性：临床试验的系统评价。
Crit Rev Oncol Hematol. 2021 Jan;157:103197. doi: 10.1016/j.critrevonc.2020.103197. Epub 2020 Dec 10.
10
Efficacy and Safety of Pembrolizumab Monotherapy or Combined Therapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.帕博利珠单抗单药或联合治疗转移性三阴性乳腺癌患者的疗效和安全性：随机对照试验的系统评价和荟萃分析。
Curr Gene Ther. 2024;25(1):72-88. doi: 10.2174/0115665232283880240301035621.

本文引用的文献

1
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities.乳腺癌中的肿瘤突变负荷：当前证据、挑战与机遇
Cancers (Basel). 2023 Aug 7;15(15):3997. doi: 10.3390/cancers15153997.
2
Microsatellite instability in noncolorectal and nonendometrial malignancies in patients with Lynch syndrome.林奇综合征患者中非结直肠癌和非子宫内膜恶性肿瘤中的微卫星不稳定性。
J Natl Cancer Inst. 2023 Jul 6;115(7):853-860. doi: 10.1093/jnci/djad063.
3
Lynch Syndrome Genetics and Clinical Implications.林奇综合征遗传学及其临床意义。
Gastroenterology. 2023 Apr;164(5):783-799. doi: 10.1053/j.gastro.2022.08.058. Epub 2023 Jan 24.
4
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.帕博利珠单抗联合化疗治疗晚期三阴性乳腺癌。
N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809.
5
Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome.林奇综合征个体中发生的乳腺癌的形态学和基因组特征。
Clin Cancer Res. 2022 Jan 15;28(2):404-413. doi: 10.1158/1078-0432.CCR-21-2027. Epub 2021 Oct 19.
6
Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance.肿瘤突变负担和错配修复缺陷不匹配作为免疫治疗耐药的机制。
J Natl Compr Canc Netw. 2021 Feb 2;19(2):130-133. doi: 10.6004/jnccn.2020.7680. Print 2021 Feb.
7
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.帕博利珠单抗治疗微卫星高度不稳定型晚期结直肠癌。
N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699.
8
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.TBCRC 048：奥拉帕利治疗转移性乳腺癌及同源重组相关基因变异的 II 期研究。
J Clin Oncol. 2020 Dec 20;38(36):4274-4282. doi: 10.1200/JCO.20.02151. Epub 2020 Oct 29.
9
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.在 GeparNuevo 研究中，肿瘤突变负担和免疫浸润是新辅助免疫检查点抑制治疗早期三阴性乳腺癌反应的独立预测因素。
Ann Oncol. 2020 Sep;31(9):1216-1222. doi: 10.1016/j.annonc.2020.05.015. Epub 2020 May 24.
10
Pembrolizumab for Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌。
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.